Evidence map›Paper›PMID 31649855›Full record

ArticleActa pharmaceutica Sinica. B2019

The dimerization of

Arben Cuadari, Federica Pollastro, Juan D Unciti-Broceta, Diego Caprioglio, Alberto Minassi, Annalisa Lopatriello, Eduardo Muñoz, Orazio Taglialatela-Scafati, Giovanni Appendino

Open access · diamondAbstract read
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. ΔBritish journal of pharmacology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Arben CuadariDipartimento di Scienze del Farmaco, Università del Piemonte Orientale, Novara 28100, Italy.
Federica PollastroDipartimento di Scienze del Farmaco, Università del Piemonte Orientale, Novara 28100, Italy.
Juan D Unciti-BrocetaEmerald Health Biotechnology España, Calle Cecilia Payne, Córdoba 14014, Spain.
Diego CaprioglioDipartimento di Scienze del Farmaco, Università del Piemonte Orientale, Novara 28100, Italy.
Alberto MinassiDipartimento di Scienze del Farmaco, Università del Piemonte Orientale, Novara 28100, Italy.
Annalisa LopatrielloDipartimento di Farmacia, Università di Napoli Federico II, Napoli 80131, Italy.
Eduardo MuñozMaimonides Biomedical Research Institute of Córdoba, Cordoba 14004, Spain.
Orazio Taglialatela-ScafatiDipartimento di Farmacia, Università di Napoli Federico II, Napoli 80131, Italy.
Giovanni AppendinoDipartimento di Scienze del Farmaco, Università del Piemonte Orientale, Novara 28100, Italy.
Università degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITUniversity of Naples Federico II · ITInstituto Maimónides de Investigación Biomédica de Córdoba · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The renewed interest in dimeric salicylates as broad-spectrum anti-inflammatory and anti-diabetic agents provided a rationale to investigate the dimerization of the substituted salicylate

Indexed as

DimerizationPhytocannabinoidsPPAR-γΔ9-TetrahydrocannabinolΔ9-Tetrahydrocannabinolic acid A

Identifiers

PMID31649855
PMCPMC6804457
OpenAlexW2953555022

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.